Top

Published in:

01-09-2008 | Epidemiology

Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer

Authors: Kari Hemminki, Hui Zhang, Jan Sundquist, Justo Lorenzo Bermejo

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

An increased risk of second primary cancers may depend on many reasons, including therapy for the first cancer and heritable causation. Population level data are not available exploring the risks of subsequent cancers after breast cancer considering a familial history of breast cancers. We used the nation-wide Swedish Family-Cancer Database to investigate such risks, based on 43,398 first invasive female breast cancers. Standardized incidence ratios (SIRs) were calculated for the second cancer after breast cancer using rates for first cancer as a reference. Many cancers at discordant sites were increased after breast cancer. SIRs for subsequent neoplasms in women who had a family history of breast cancer were increased for ovarian (2.0) and endometrial (1.8) cancers and for acute lymphoid leukemia (12.7) and myelofibrosis (9.4). The data suggest that the familial aggregation of breast and endometrial cancers may be explained by yet unidentified heritable causes. The remarkably high risks for second acute lymphoid leukemia and myelofibrosis, both characterized by chromosomal aberrations, in women with a family history of breast cancer may signal heritable defects in the ability to process DNA damage caused by ionizing radiation and chemotherapy.

Travis LB (2006) The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 15:2020–2026PubMedCrossRef

Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB et al (2006) Cancer survivorship−genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98:15–25PubMed

Hemminki K, Boffetta P (2004) Multiple primary cancers as clues of environmental and heritable courses of cancer and of mechanisms of carcinogenesis. IARC Sci Publ 157:289–297PubMed

Dong C, Hemminki K (2001) Second primary neoplasms in 633964 cancer patients in Sweden, 1958–1996. Int J Cancer 93:155–161PubMedCrossRef

Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A et al (2005) Second primary cancers among 109 000 cases of non-Hodgkin’s lymphoma. Br J Cancer 93:159–166PubMedCrossRef

Hemminki K, Scelo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A et al (2005) Second primary malignancies in patients with male breast cancer. Br J Cancer 92:1288–1292PubMedCrossRef

Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E et al (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292PubMedCrossRef

Chappuis P, Rosenblatt J, Foulkes W (1999) The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 10:1163–1170PubMedCrossRef

Vaittinen P, Hemminki K (2000) Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 88:998–1002PubMedCrossRef

10.

Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D et al (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382PubMedCrossRef

11.

Hemminki K, Ji J, Forsti A (2007) Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67:868–870PubMedCrossRef

12.

Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J (2005) Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 366:1554–1557PubMedCrossRef

13.

Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051–1057PubMedCrossRef

14.

Pal T, Flanders T, Mitchell-Lehman M, MacMillan A, Brunet J, Narod S et al (1998) Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet 35:978–984PubMedCrossRef

15.

Hemminki K, Vaittinen P, Easton D (2000) Familial cancer risks to offspring from mothers with two primary breast cancers: leads to cancer syndromes. Int J Cancer 88:87–91PubMedCrossRef

16.

Hemminki K, Granström C, Sundquist J, Lorenzo Bermejo J (2006) The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Heredit Cancer Clin Pract 4:186–192CrossRef

17.

Centre for Epidemiology (2007) Cancer incidence in Sweden 2005. The National Board of Health and Welfare, Stockholm

18.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRef

19.

Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871PubMedCrossRef

20.

The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(91):1310–1316CrossRef

21.

Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365PubMed

22.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706PubMedCrossRef

23.

Lorenzo Bermejo J, Hemminki K (2004) Familial association of histology specific breast cancers with cancers at other sites. Int J Cancer 109:430–435PubMedCrossRef

24.

Lorenzo Bermejo J, Buchner FL, Hemminki K (2004) Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC Ann Oncol 15:598–604PubMedCrossRef

25.

Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932PubMedCrossRef

26.

Jaffe E, Harris N, Stein H, Vardiman J (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

27.

Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131–1135PubMedCrossRef

28.

Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308–1314PubMedCrossRef

29.

Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319PubMedCrossRef

30.

Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873–875PubMedCrossRef

31.

Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241PubMedCrossRef

32.

Steffen J, Nowakowska D, Niwinska A, Czapczak D, Kluska A, Piatkowska M et al (2006) Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 119:472–475PubMedCrossRef

Title: Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer
Authors: Kari Hemminki
Hui Zhang
Jan Sundquist
Justo Lorenzo Bermejo
Publication date: 01-09-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9759-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan

Medical cost-offsets from psychosocial care in breast cancer

The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer

MAZ drives tumor-specific expression of PPAR gamma 1 in breast cancer cells

The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study

Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer